(firstQuint)Bioequivalence Study of Clorazepate Dipotassium 15mg Tablets Under Fasting Conditions.

 The study was conducted as an open label, balanced, randomised, two-treatment, two-period, two-sequence, single-dose, crossover , bioequivalence study on clorazepate dipotassium comparing clorazepate dipotassium 15mg tablets of Ranbaxy Laboratories with Abbott (TranxeneeT-Tab(R)) 15 mg, in healthy, adult, human, subjects under fasting conditions.

 A total of 32 subjects, 25 males and 7 females, were enrolled in the study, and 31 subjects, 24 males and 7 females, completed the study.

.

 Bioequivalence Study of Clorazepate Dipotassium 15mg Tablets Under Fasting Conditions@highlight

The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Abbott (TranxeneeT-Tab(R)) 15 mg clorazepate dipotassium tablets under fasting conditions.

